The sharp drop in target price combines the hard reality of 2015 which recorded another major loss and the 2016 own set of problems, including the dilutive costs of equity financing rounds. The H2 performance of the core project - waste to power - is pointing to a "worst behind" status.
26 Sep 2016
Pain still the 2016 order of the day (Europlasma)
Sign up to access
Get access to our full offering from over 30 providers
Get access to our full offering from over 30 providers
Pain still the 2016 order of the day (Europlasma)
The sharp drop in target price combines the hard reality of 2015 which recorded another major loss and the 2016 own set of problems, including the dilutive costs of equity financing rounds. The H2 performance of the core project - waste to power - is pointing to a "worst behind" status.